Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.

导出原文传递

翻译打印收藏纠错

第一作者： Sam,Keeping

第一单位： Precision HEOR, Vancouver, BC V6H 3Y4, Canada.

作者： Sam,Keeping ^[1] ; Yingxin,Xu ^[2] ; Chieh-I,Chen ^[2] ; Shannon,Cope ^[1] ; Ali,Mojebi ^[1] ; Andreas,Kuznik ^[2] ; Gerasimos,Konidaris ^[3] ; Dieter,Ayers ^[1] ; Medha,Sasane ^[4] ; Rachel,Allen ^[3] ; Thi-Minh-Thao,Huynh ^[5] ; Evan,Popoff ^[1] ; Morganna,Freeman ^[6] ; Michael L,Andria ^[2] ; Matthew G,Fury ^[2] ; Kanwarjit,Singh ^[4] ; Eggert,Stockfleth ^[7] ; Amarnath,Challapalli ^[8] ; Chrysalyne D,Schmults ^[9]

作者单位： Precision HEOR, Vancouver, BC V6H 3Y4, Canada. ^[1] Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. ^[2] Sanofi, Reading, RG6 1PT, UK. ^[3] Sanofi, Bridgewater, NJ 08807, USA. ^[4] Sanofi, Chilly-Mazarin, 91380, France. ^[5] City of Hope, Duarte, CA 91010, USA. ^[6] Department of Dermatology, University of Bochum, 44801 Bochum, Germany. ^[7] Bristol Cancer Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, BS2 8ED, UK. ^[8] Brigham & Women's/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. ^[9]

关键词 cemiplimab cutaneous squamous cell carcinoma immuno-oncology indirect treatment comparison nonmelanoma skin cancer

主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);卡铂(Carboplatin);癌, 鳞状细胞(Carcinoma, Squamous Cell);顺铂(Cisplatin);临床试验(主题)(Clinical Trials as Topic);人类(Humans);皮肤肿瘤(Skin Neoplasms)

DOI 10.2217/fon-2020-0823

PMID 33052055

发布时间 2021-09-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交